微小残留病在监测儿童急性T淋巴细胞白血病复发中的意义  

Clinical significance of minimal residual disease in monitoring relapse of childhood acute T-cell lymphoblastic leukemia

作　　者：张瑞东[1] 刘怡[1] 张永红[1] 谢静[1] 姜锦[1] 王斌[1] 郑胡墉 李志刚[1] 吴敏媛[1] 

机构地区：[1]首都医科大学附属北京儿童医院血液病中心儿科学国家重点学科省部共建儿科重大疾病研究重点实验室,北京100045

出　　处：《中国小儿血液与肿瘤杂志》2011年第5期203-206,共4页Journal of China Pediatric Blood and Cancer

基　　金：北京市科委资助项目"儿童急性淋巴细胞白血病微小残留病定量及其对个体化治疗的作用"(项目编号:D0905001040431)

摘　　要：目的探讨微小残留病(MRD)监测急性T淋巴细胞白血病患儿复发的临床指导意义。方法采用四色流式细胞术对2006年8月1日-2008年4月1日32例急性T淋巴细胞白血病住院患儿在治疗不同时间点进行追踪监测,分析不同MRD水平与患儿的临床反应及复发之间的关系。结果诱导治疗第33天以及诱导治疗结束巩固治疗前(治疗12周)MRD<10-4和≥10-4两组患儿的复发率差异有显著性(P=0.003,P=0.002)。结论监测急性T淋巴细胞白血病患儿MRD水平,在评估早期治疗反应、监测复发以及估计预后中具有重要临床价值。ObjectiveTo observe the clinical significance of monitoring minimal residual disease in childhood acute T-cell lymphoblastic leukemia.MethodsMinimal residual disease level of 32 children with T-cell ALL from 2006.8.1-2008.4.1 were monitored by 4-color flow cytometry in different therapy time point.The relationship between minimal residual disease level and early treatment response,as well as relapse were studied.ResultsThere were significant differences between the relapse and complete remission groups divided by MRD level（MRD≥10^-4 or MRD10^-4） in the early 33rd day of induction therapy and before consolidation therapy.The P values were 0.003 and 0.002 respectively.ConclusionSequential monitoring MRD by 4-color follow cytometry in different therapy time point could evaluate the early response and provides highly significant prognostic information in children with T-cell ALL.

关 键 词：白血病 T淋巴细胞型 急性 儿童 微小残留病 

分 类 号：R733.71[医药卫生—肿瘤]